Express Mail Label No.: EV473991850US Date of Deposit: September 22, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Shimkets

SERIAL NUMBER:

10/644,349

EXAMINER:

Not Yet Assigned

Atty. Docket No. 15966-557 PO (CURA 57 PO)

FILING DATE:

August 20, 2003

ART UNIT:

For:

SEP 2 2 2005

METHODS FOR DIAGNOSING AND TREATMENT OF CONDITIONS THAT

ALTER PHOSPHATE TRANSPORT IN MAMMALS

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents which were previously filed on August 15, 2005. A copy of these documents are now being transmitted separately to each case listed on Schedule A, so the documents can be more easily matched up with the relevant file.

- 1. Revocation by Assignee and New Power of Attorney (2 pgs.) with attached Schedule A (4 pgs.);
- 2. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 15966-557 PO (CURA 57 PO). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529 Naomi S. Biswas. No. 38,384

Attorneys for Applicant

c/o MINTZ LEVIN Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: September 22, 2005

Customer No. 30623

Attorney Docket No.

SEP 2 2 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE:

CuraGen Corporation

SERIAL NUMBER:

See Attached Schedule A

FILING DATE:

See Attached Schedule A

For:

See Attached Schedule A

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CuraGen Corporation, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to <u>Ivor R. Elrifi</u> at telephone number 617/348-1747. Please address all correspondence to Customer No. 55111.

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,

George M. Yahwak, Esq.

TITIE: Director of Intellectual Property

REGISTRATION NO. 26, 824

COMPANY: CuraGen Corporation

Date: Monday, August 15, 2005

TRA 2055379v1



U.S. APPLICATIONS

| Dööket Nö | Title | Filling Date | Application No | Assignment Reel and Hame Nosi |
|-----------------------|--|------------------|-------------------|-------------------------------------|
| 21402-018 | Method of Detecting Inflammatory Lung Disorders | May 25, 2001 | 09/865,812 | R# |
| CURA 318 | | | | r# Abandoned |
| 21402-018 DIV | Method of Detecting Inflammatory Lung Disorders | July 2, 2003 | 10/613,105 | R# F# |
| CURA 318 DIV | Mathada of Detection and Treating Tuberous Sclerosis | Dec. 10, 2001 | 10/016,253 | R#013294 |
| 21402-042 CURA 342 | Complex Associated Disorders | | | F#0484 |
| 21402-048 | Therapeutic Polypeptides, Nucleic Acids Encoding | March 19, 2003 | 10/391,939 | R3 F# |
| CURA 348 | Therangutic Polypeptides, Nucleic Acids Encoding | Dec. 2, 2002 | 10/309,290 | R#013968 |
| CURA 802A | Same, and Methods of Use | | | F#0584 |
| 21402-660 | Compositions and Methods for Treating T-Cell | January 31, 2005 | 11/047,207 | R# |
| CURA 960 | Mediated Pathological Conditions | | | F# |
| 15966-557OM | Compositions and Methods of Use for a Fibroblast | May 9, 2003 | 10/435,087 | R#015013 |
| CURA 570M | Growth Factor | | | F#0343 |
| | | | | |

| DocketiNb | Tille | Filing Date | Application Mo: | Assigninant Regland Frame Nost |
|--------------------------------|--|----------------------|--------------------|--------------------------------------|
| 15966-557 IBD CIP3 | Methods of Preventing an Treating Inflammatory Bowel Disease | Nov. 3, 2004 | 10/890,764 | R# F# |
| CURA571BDCIP3 | | | , | |
| 15966-557A IBDCIP2 | Treatment of Inflammatory Bowel Disease Using Growth Factors | Dec. 16, 2002 | 10/321,962 | R# F# |
| CURA 57 A IBD CIP2 | | | | |
| 15966-557A IBDCIP | Treatment of Inflammatory Bowel Disease Using Growth Factors | November 16, 2001 | 10/011,364 | R# F# |
| CURA 57 A IBDCIP | | | | |
| 15966-557 CON CURA 57 CON | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | December 30, 2004 | 11/027,948 | R# F# |
| 15966-557 CIP4 CURA 57CIP4 | Novel Fibroblast Grown Factor and Nucleic Acids Encoding Same | Nov. 3, 2004 | 10/980,659 | R# F# |
| 15966-557 CIP3 CURA 57 CIP3 | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | June 17, 2002 | 10/174,394 | R#013630 F#0882 |
| 15966-557 CIP2CON1 | Antibodies to Fibroblast Growth Factor and Their Methods of Use | Sept. 23, 2004 | 10/948,588 | R# F# |
| CURA 57 CIP2CON1 | | | | |

| Dockel No | Title | Filing Date | Application No. | Assignment Reel and Frame Nos |
|------------------------------------|---|-----------------|--------------------|-------------------------------------|
| 15966-557 CIP1 | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | July 3, 2000 | 09/609,543 | R#011317 F#0748 |
| 15966-557A | Treatment of Inflammatory Bowel Disease Using Growth Factors | Nov. 6, 2001 | 09/992,840 | R#015497 F#0582 |
| 15966-557 OA CIP | Fibroblast Growth Factor 20 and Methods of Use Thereof | Nov. 3, 2004 | 10/980,458 | R# F# |
| 15966-557 OA | Novel Fibroblast Growth Factors and Methods of Use Thereof | May 10, 2004 | 10/842,206 | R# F# |
| 15966-557RP CIP1 CURA 57RP CIP1 | Prophylactic and Therapeutic Uses of FGF-20 in Radiation Protection | Nov. 3, 2004 | 10/980,695 | R# F# |
| 15966-557 RP CURA 57 RP | Therapeutic Use of G53135-05 (FGF-20) in Radiation Protection | May 10, 2004 | 10/842,179 | R# F# |
| 15966-557 SNP CURA 57 SNP | Compositions and Methods of Use For a Fibroblast Growth Factor | Nov. 4, 2003 | 10/702,126 | R# F# |
| 15966-557 PO CURA 57 PO | Methods For Diagnosing and Treatment of Conditions That Alter Phosphate Transport in Mammals | August 20, 2003 | 10/644,349 | R#014925 F#0846 |
| 15966-557 FP CURA 57 FP | Formulations and Methods of Production of FGF-20 | Nov. 3, 2004 | 10/980,370 | К# F# |
| | | | | |

| | | Filing Date | Аррцеацой No. | Assignment Reel and Frame Nos. |
|--|--|----------------------|------------------|--------------------------------------|
| 15966-557 AM M CURA 57 AM M | Method of Preventing and Treating Alimentary Mucositis | Nov. 3, 2004 | 10/980,459 | R# F# |
| 15966-577 Ga | Growth Factor Polypeptides and Nucleic Acids Encoding Same | Sept. 12, 2000 | 09/688,312 | R#015523 F#0696 |
| 15966-577 CON Gr CURA 77 CON Ex | Growth Factor Polypeptides and Nucleic Acids Encoding Same | April 1, 2005 | 11/096,308 | R# F# |
| 15966-577 A Gr CURA 77 A Ex | Growth Factor Polypeptides and Nucleic Acids. Encoding Same | October 5, 2000 | 09/685,330 | R#011534 F#0346 Abandoned |
| 15966-577A CIP Gr CURA 77A CIP Et | Growth Factor Polypeptides and Nucleic Acids Encoding Same | October 13, 2000 | 09/688,312 | R# F# Abandoned |
| 15966-577A CIP2 Gi CURA 77A CIP2 Ei | Growth Factor Polypeptides and Nucleic Acids Encoding Same | November 16, 2000 | 09/717,332 | R# F# Abandoned |
| 15966-577A CIP3 Gi CURA 77A CIP3 Ei | Growth Factor Polypeptides and Nucleic Acids Encoding Same | February 2, 2001 | 09/775,482 | R#012218 F#0294 Abandoned |